Memorial Sloan-Kettering Will Not Offer Zaltrap

Memorial Sloan-Kettering Cancer Center made a very public announcement—and explanation—today in a New York Times op-ed about why they will not offer the new drug Zaltrap® (ziv-aflibercept) to its metastatic colorectal cancer patients. The authors, all world-renowned cancer specialists at the…  Read More

Positive News for VEGF Trap in Colorectal Cancer

ZALTRAP® (aflibercept) added to survival time when given along with FOLFIRI to colorectal cancer patients who had already progressed on earlier oxaliplatin treatment. On April 26, 2011, sanofi-aventis and Regeneron Pharmaceuticals announced positive results for the Phase III VELOUR trial,…  Read More